Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Oppenheimer's Rating of Aardvark Therapeutics on 10/26/2026

On October 26, 2026, Oppenheimer updated its outlook on Aardvark Therapeutics (NASDAQ:AARD) with the action "Downgrade", setting a "Market Perform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
10/26/2026
MSC Income Fund stock logo
MSIF
MSC Income Fund
Initiated Coverage
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated Rating
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Set Price Target
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated Rating
10/26/2026
Datadog, Inc. stock logo
DDOG
Datadog
Boost Price Target
10/26/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price Target
More Ratings From Oppenheimer Holdings, Inc.